Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 1, Single Dose, Randomized, Parallel-group Study to Evaluate the Relative Bioavailability of Two Evolocumab (AMG 145) Drug Products

NCT07422285 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT07422285
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07422285 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 1, Single Dose, Randomized, Parallel-group Study to Evaluate the Relative Bioavailability of Two Evolocumab (AMG 145) Drug Products
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
January 16, 2026
Completion date
July 24, 2026
Enrollment
405 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants, pharmacokinetics